Stroke, Acute Clinical Trial
— STRIPEOfficial title:
Stent Retriever Versus Contact Aspiration in Irregular Occlusion Phenotype, a Novel Approach in the Endovascular Treatment of Acute Ischemic Stroke: the STRIPE Randomized Trial.
Patients with a clinico-neuroradiological mismatch pattern shown on the magnetic resonance imaging/Computed Tomography in the acute phase of stroke are more likely to benefit from reperfusion, are suitable candidates for endovascular therapy, and have a better clinical prognosis. The ASTER Trial showed similar results between stent-retrievers and contact aspiration concerning the recanalization grade in anterior circulation occlusions. However, we still observe late and futile recanalizations, secondary either to extended ischemic lesions at baseline, long-time procedures or intraprocedural complications. The First Pass Effect that is the complete/nearly complete recanalization after the first maneuver, independently on the technique used, has been strongly associated with better clinical outcomes . In a recent paper we proposed a novel approach to identify those cases that could be treated with a specific technique (stent-retriever) with higher chances to achieve a complete or nearly complete recanalization, with lower procedure times and lower complication rates. This approach is focused on the identification of a regular or irregular phenotype of the occlusion site in patients with an M1-Middle Cerebral Artery occlusion. The phenotype is defined as "regular" whether the profile of the occlusion is abruptly cut without any irregularity and as "irregular" if any irregularity of the profile of the occlusion is observed. One of the hypotheses that could explain these results could be related to the composition of the clot : a soft and less organized clot could be more easily flattened by the pulsatile flow and therefore determine a regular aspect of the occlusion. A more solid and organized clot would, on the contrary, maintain an irregular profile because it would not be flattened by the blood flow and the contrast medium could highlight the irregularities of the proximal face of the clot. The latter could be a favorable target for the use of a stent-retriever since the interaction between a solid clot and the struts of the stent could increase the chance to retrieve the clot. Therefore, we propose this randomized controlled trial to assess the superiority of stent-retrievers compared to contact aspiration in the treatment of irregular phenotype occlusions of the M1-Middle Cerebral Artery.
Status | Recruiting |
Enrollment | 356 |
Est. completion date | November 1, 2025 |
Est. primary completion date | February 1, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Age = 18 years - M1-Middle Cerebral Artery occlusion - Eligible for mechanical thrombectomy: groin puncture performed within 24 hours from the first symptoms or from the last time the patient was seen normal. - Presence of a mismatch on Magnetic resonance imaging MRI or CT (computed tomography) scan - Baseline mRS <2 - Irregular occlusion phenotype on the first angiographic run - Informed consent obtained from the patients/his proxy or following an emergency procedure - Being covered by a national health insurance Exclusion Criteria: - Isolated M2 occlusions - Clinical history, past imaging or clinical judgment suggesting underlying intracranial stenosis - Severe contrast medium allergy or absolute contraindication to use of iodinated products - Patients with severe or fatal comorbidities that will likely prevent improvement or follow-up, or that will render the procedure unlikely to benefit the patient - Angiographic evidence of carotid dissection or tandem cervical occlusion or stenosis requiring treatment - Pregnancy (urine or serum beta HCG test for women of child-bearing potential) - Patient benefiting from a legal protection (guardianship or curatorship) - Being deprived of liberty |
Country | Name | City | State |
---|---|---|---|
France | Chu Bordeaux | Bordeaux | |
France | CHU Montpellier | Montpellier | |
France | Chru Nancy | Nancy | |
France | Chu Nantes | Nantes | |
France | APHP - Pitié Salpêtrière | Paris | |
France | Fondation Adolphe de Rothschild | Paris | |
France | CHU de Reims | Reims | |
France | Hôpital FOCH | Suresnes | |
France | CHU de Tours | Tours |
Lead Sponsor | Collaborator |
---|---|
Hopital Foch |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Rate of favorable functional outcome at 90-day defined by a Modified Rankin Scale (mRS) 0-2 | mRS is evaluated between 0 to 6. A score of 0 indicates that there is no disability and a score of 6 indicates death | 3 months | |
Secondary | Rate of patients with first pass effect (FPE) defined as mTICI 2c/3 after first device maneuver | The definition of FPE: single pass/use of the device, (2) complete revascularization of the large vessel occlusion and its downstream territory (mTICI 3), and (3) no use of rescue therapy | 24 hours | |
Secondary | Rates of patients with complete (mTICI 3), perfect (mTICI 2c/3) and successful reperfusion (mTICI 2b/3) at the end of endovascular procedure | mTICI (modified Thrombolysis In Cerebral Infarction ) score equals to 3 after the first line thrombectomy and at the end of endovascular.
mTICI score is evaluated between 0-3 : 0 a complete obstruction of the artery and 3 indicates a complete reperfusion |
24 hours | |
Secondary | Time from groin puncture to achieve the maximum recanalization | The time between the groin puncture and the maxiamum recanalization will be assessed | 24 hours | |
Secondary | Rate of patients who will require less than 2 device pass | Rate of patients who require less than 2 devices pass | 24 hours | |
Secondary | Rate of patients with rescue therapy use | Rate of patient with other than one pass with thrombectomy device | 24 hours | |
Secondary | Degree of disability assessed by overall distribution of the mRS at 90 days and one year (shift analysis combining scores of 5 and 6) | overall distribution of the mRS at 90 days and one year | 12 months | |
Secondary | Rate of all-cause mortality at 90 day and one year | number of mortality at 90 days and on year | 12 months | |
Secondary | 24 hours change in NIHSS from baseline defined as the difference between NIHSS score at 24 hours and NIHSS score at admission | NIHSS (National Institutes of Health Stroke Scale) score is evaluated between 0-42 0 is normal and 42 maximal gravity | 24 hours | |
Secondary | Incidence of intracerebral haemorrhage (ICH), parenchymal hematoma, symptomatic ICH, on brain imaging (Magnetic resonance imaging MRI or CT (computed tomography) scan) at 24 hours after thrombectomy (according to ECASS3 classification) | ECASS III (European Cooperative Acute Stroke Study) classification :
Hemorrhage infarction type 1 (HI1) Hemorrhage infarction type 2 (HI2) Parenchymal hematoma type 1 (PH1) Parenchymal hematoma type 2 (PH2) |
24 hours | |
Secondary | Incidence of procedure-related complications such as arterial perforation or dissection, embolization in new territory | arterial perforation or dissection, embolization in new territory | 48 hours |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05378035 -
DOAC in Chinese Patients With Atrial Fibrillation
|
||
Completed |
NCT03574038 -
Transcranial Direct Current Stimulation as a Neuroprotection in Acute Stroke
|
N/A | |
Completed |
NCT03679637 -
Tablet-based Aphasia Therapy in the Acute Phase After Stroke
|
N/A | |
Completed |
NCT03633422 -
Evaluation of Stroke Patient Screening
|
||
Completed |
NCT04088578 -
VNS-supplemented Motor Retraining After Stroke
|
N/A | |
Withdrawn |
NCT04991038 -
Clinical Investigation to Compare Safety and Efficacy of DAISE and Stent Retrievers for Thrombectomy In Acute Ischemic Stroke Patients
|
N/A | |
Not yet recruiting |
NCT05534360 -
Tenecteplase Treatment in Ischemic Stroke Registry
|
||
Not yet recruiting |
NCT04105322 -
Effects of Kinesio Taping on Balance and Functional Performance in Stroke Patients
|
N/A | |
Withdrawn |
NCT05786170 -
ERILs Und SNILs Unter SOC
|
N/A | |
Recruiting |
NCT03132558 -
Contrast Induced Acute Kidney in Patients With Acute Stroke
|
N/A | |
Completed |
NCT02893631 -
Assessment of Hemostasis Disorders in rtPA-treated Patients Requiring Endovascular Treatment for Ischemic Stroke
|
||
Active, not recruiting |
NCT02274727 -
Biomarker Signature of Stroke Aetiology Study: The BIOSIGNAL-Study
|
||
Completed |
NCT02225730 -
Imaging Collaterals in Acute Stroke (iCAS)
|
||
Terminated |
NCT01705353 -
The Role of HMGB-1 in Chronic Stroke
|
N/A | |
Active, not recruiting |
NCT01581502 -
SAMURAI-NVAF Study: Anticoagulant Therapy for Japanese Stroke Patients With Nonvalvular Atrial Fibrillation (NVAF)
|
N/A | |
Completed |
NCT01182818 -
Fabry and Stroke Epidemiological Protocol (FASEP): Risk Factors In Ischemic Stroke Patients With Fabry Disease
|
N/A | |
Completed |
NCT00761982 -
Autologous Bone Marrow Stem Cells in Middle Cerebral Artery Acute Stroke Treatment.
|
Phase 1/Phase 2 | |
Completed |
NCT00535197 -
Autologous Bone Marrow Stem Cells in Ischemic Stroke.
|
Phase 1/Phase 2 | |
Terminated |
NCT00132509 -
FRALYSE Trial: Comparison of the Classical Rt-PA Procedure With a Longer Procedure in Acute Ischemic Stroke
|
Phase 2 | |
Recruiting |
NCT05760326 -
Diagnostic and Prognostic Role of Clot Analysis in Stroke Patients
|